[1]
|
Kerner, W., Brückel, J. and German Diabetes Association (2014) Definition, Classification and Diagnosis of Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes, 122, 384-386. https://doi.org/10.1055/s-0034-1366278
|
[2]
|
Kharroubi, A.T. and Darwish, H.M. (2015) Diabetes Mellitus: The Epidemic of the Century. World Journal of Diabetes, 6, 850-867. https://doi.org/10.4239/wjd.v6.i6.850
|
[3]
|
Inzucchi, S.E. and Majumdar, S.K. (2016) Current Therapies for the Medical Management of Diabetes. Obstetrics and Gynecology, 27, 780-794. https://doi.org/10.1097/AOG.0000000000001332
|
[4]
|
Chillaron, J.J., Flores Le-Roux, J.A., Benaiges, D. and Pedro-Botet, J. (2014) Type 1 Diabetes, Metabolic Syndrome and Cardiovascular Risk. Metabolism, 63, 181-187. https://doi.org/10.1016/j.metabol.2013.10.002
|
[5]
|
DeWitt, D.E. and Hirsch, I.B. (2003) Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review. JAMA, 289, 2254-2264. https://doi.org/10.1001/jama.289.17.2254
|
[6]
|
Gilroy, C.A., Luginbuhl, K.M. and Chilkoti, A. (2015) Controlled Release of Biologics for the Treatment of Type 2 Diabetes. Journal of Controlled Release, 240, 151-164. https://doi.org/10.1016/j.jconrel.2015.12.002
|
[7]
|
Mooradian, A.D., Bernbaum, M. and Albert, S.G. (2006) Narrative Review: A Rational Approach to Starting Insulin Therapy. Annals of Internal Medicine, 145, 125-134. https://doi.org/10.7326/0003-4819-145-2-200607180-00010
|
[8]
|
Xu, L., Li, Y., Dai, Y. and Peng, J. (2018) Natural Products for the Treatment of Type 2 Diabetes Mellitus: Pharmacology and Mechanisms. Pharmacological Research, 130, 451-465. https://doi.org/10.1016/j.phrs.2018.01.015
|
[9]
|
Thomas, C.C. and Philipson, L.H. (2015) Update on Diabetes Classification. Medical Clinics of North America, 99, 1-16. https://doi.org/10.1016/j.mcna.2014.08.015
|
[10]
|
Roden, M. and Shulman, G.I. (2019) The Integrative Biology of Type 2 Diabetes. Nature, 576, 51-60. https://doi.org/10.1038/s41586-019-1797-8
|
[11]
|
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., et al. (2020) Pathophysiology of Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 21, Article No. 6275. https://doi.org/10.3390/ijms21176275
|
[12]
|
Santoro, A. and Kahn, B.B. (2023) Adipocyte Regulation of Insulin Sensitivity and the Risk of Type 2 Diabetes. New England Journal of Medicine, 388, 2071-2085. https://doi.org/10.1056/NEJMra2216691
|
[13]
|
Amutha, A. and Mohan, V. (2016) Diabetes Complications in Childhood and Adolescent Onset Type 2 Diabetes—A Review. Journal of Diabetes Complications, 30, 951-957. https://doi.org/10.1016/j.jdiacomp.2016.02.009
|
[14]
|
Van Belle, T.L., Coppieters, K.T. and Von Herrath, M.G. (2011) Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies. Physiological Reviews, 91, 79-118. https://doi.org/10.1152/physrev.00003.2010
|
[15]
|
Salazar, J., Navarro, C., Ortega, á., Nava, M., Morillo, D., Torres, W., Hernández, M., et al. (2021) Advanced Glycation End Products: New Clinical and Molecular Perspectives. International Journal of Environmental Research and Public Health, 18, Article No. 7236. https://doi.org/10.3390/ijerph18147236
|
[16]
|
Singh, V.P., Bali, A., Singh, N. and Jaggi, A.S. (2014) Advanced Glycation End Products and Diabetic Complications. Korean Journal of Physiology & Pharmacology, 18, 1-14. https://doi.org/10.4196/kjpp.2014.18.1.1
|
[17]
|
Engwa, G.A., Ennwekegwa, F.N. and Nkeh-Chungag, B.N. (2022) Free Radicals, Oxidative Stress-Related Diseases and Antioxidant Supplementation. Alternative Therapies in Health and Medicine, 28, 114-128.
|
[18]
|
Asmat, U., Abad, K. and Ismail, K. (2016) Diabetes Mellitus and Oxidative Stress—A Concise Review. Saudi Pharmaceutical Journal, 24, 547-553. https://doi.org/10.1016/j.jsps.2015.03.013
|
[19]
|
Yan, L.J. (2018) Redox Imbalance Stress in Diabetes Mellitus: Role of the Polyol Pathway. Animal Models and Experimental Medicine, 1, 7-13. https://doi.org/10.1002/ame2.12001
|
[20]
|
Das Evcimen, N. and King, G.L. (2007) The Role of Protein Kinase C Activation and the Vascular Complications of Diabetes. Pharmacology Research, 55, 498-510. https://doi.org/10.1016/j.phrs.2007.04.016
|
[21]
|
Dierschke, S.K. and Dennis, M.D. (2022) Retinal Protein O-Glcnacylation and the Ocular Renin-Angiotensin System: Signaling Cross-Roads in Diabetic Retinopathy. Current Diabetes Reviews, 18, e011121190177. https://doi.org/10.2174/1573399817999210111205933
|
[22]
|
Unuofin, J.O. and Lebelo, S.L. (2020) Antioxidant Effects and Mechanisms of Medicinal Plants and Their Bioactive Compounds for the Prevention and Treatment of Type 2 Diabetes: An Updated Review. Oxidative Medicine and Cellular Longevity, 2020, Article ID: 1356893. https://doi.org/10.1155/2020/1356893
|
[23]
|
Osadebe, P.O., Odoh, E.U. and Uzor, P.F. (2014) Natural Products as Potential Sources of Antidiabetic Drugs. Journal of Pharmaceutical Research International, 1, 2075-2095. https://doi.org/10.9734/BJPR/2014/8382
|
[24]
|
Safavi, M., Foroumadi, A. and Abdollahi, M. (2013) The Importance of Synthetic Drugs for Type 2 Diabetes Drug Discovery. Expert Opinion on Drug Discovery, 8, 1339-1363. https://doi.org/10.1517/17460441.2013.837883
|
[25]
|
Ahda, M., Jaswir, I., Khatib, A., Ahmed, Q.U., Mahfudh, N. and Ardini, Y.D. (2023) A Review on Selected Herbal Plants as Alternative Anti-Diabetes Drugs: Chemical Compositions, Mechanisms of Action, and Clinical Study. International Journal of Food Properties, 26, 1414-1425. https://doi.org/10.1080/10942912.2023.2215475
|
[26]
|
Mtenga, D.V. and Ripanda, A.S. (2022) A Review on the Potential of Underutilized Blackjack (Bidens pilosa) Naturally Occurring in Sub-Saharan Africa. Heliyon, 8, e09586. https://doi.org/10.1016/j.heliyon.2022.e09586
|
[27]
|
Yanqing P., Todd, L.L. and Rik, R.T. (2009) Naturally Occurring and Synthetic Polyyne Glycosides. Canadian Journal of Chemistry, 87, 1565-1582. https://doi.org/10.1139/V09-117
|
[28]
|
Chien, S.C., Young, P.H., Hsu, Y.J., Chen, C.H., Tien, Y.J., Shiu, S.Y., et al. (2009) Anti-Diabetic Properties of Three Common Bidens pilosa Variants in Taiwan. Phytochemistry, 70, 1246-1254. https://doi.org/10.1016/j.phytochem.2009.07.011
|
[29]
|
Chiang, Y.M., Chang, C.L.T., Chang, S.L., Yang, W.C. and Shyur, L.F. (2007) Cytopiloyne, A Novel Polyacetylenic Glucoside from Bidens pilosa, Functions as a T Helper Cell Modulator. Journal of Ethnopharmacology, 110, 532-538. https://doi.org/10.1016/j.jep.2006.10.007
|
[30]
|
Yang, W.C. (2014) Botanical, Pharmacological, Phytochemical, and Toxicological Aspects of the Antidiabetic Plant Bidens pilosa L. Evidence-Based Complementary and Alternative Medicine, 2014, Article ID: 698617. https://doi.org/10.1155/2014/698617
|
[31]
|
Waititu, K., Jerono, C., Kituku, D., Nzuve, M., Mambo, F., Ngugi, P., et al. (2018) Phytochemical Composition of Kalanchoe pinnata and Bidens pilosa Leaves Associated with Management of Diabetes. Biomedicine and Biotechnology, 6, 15-20.
|
[32]
|
Chung, C.Y., Yang, W.C., Liang, C.L., Liu, H.Y., Lai, S.K. and Chang, C.L.T. (2016) Cytopiloyne, A Polyacetylenic Glucoside from Bidens pilosa, Acts as a Novel Anticandidal Agent via Regulation of Macrophages. Journal of Ethnopharmacology, 184, 72-80. https://doi.org/10.1016/j.jep.2016.02.036
|
[33]
|
Ganjewala, D., Kumar, S., Ambika, K., Luthra, R., Resource, H., Group, D., et al. (2008) Plant Polyacetylenic Glycosides Occurrence, Biosynthesis and Biological Activities. Pharmacologyonline, 131, 113-131.
|
[34]
|
Xuan, T.D. and Khanh, T.D. (2016) Chemistry and Pharmacology of Bidens pilosa: An Overview. Journal of Pharmaceutical Investigation, 46, 91-132. https://doi.org/10.1007/s40005-016-0231-6
|
[35]
|
Wang, R., Wu, Q.X. and Shi, Y.P. (2010) Polyacetylenes and Flavonoids from the Aerial Parts of Bidens pilosa. Planta Medica, 76, 893-896. https://doi.org/10.1055/s-0029-1240814
|
[36]
|
Ubillas, R.P., Mendez, C.D., Jolad, S.D., Luo, J., King, S.R., Carlson, T.J., et al. (2000) Antihyperglycemic Acetylenic Glucosides from Bidens pilosa. Planta Medica, 66, 82-83. https://doi.org/10.1055/s-0029-1243117
|
[37]
|
Chang, S.L., Chang, C.L.T., Chiang, Y.M., Hsieh, R.H., Tzeng, C.R., Wu, T.K., et al. (2004) Polyacetylenic Compounds and Butanol Fraction from Bidens pilosa Can Modulate the Differentiation of Helper T Cells and Prevent Autoimmune Diabetes in Non-Obese Diabetic Mice. Planta Medica, 70, 1045-1051. https://doi.org/10.1055/s-2004-832645
|
[38]
|
Chang, C.L.T., Chang, S.L., Lee, Y.M., Chiang, Y.M., Chuang, D.Y., Kuo, H.K., et al. (2007) Cytopiloyne, A Polyacetylenic Glucoside, Prevents Type 1 Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 178, 6984-6993. https://doi.org/10.4049/jimmunol.178.11.6984
|
[39]
|
Bartolome, A.P., Villasenor, I.M. and Yang, W.C. (2013) Bidens pilosa L. (Asteraceae): Botanical Properties, Traditional Uses, Phytochemistry, and Pharmacology. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID: 340215. https://doi.org/10.1155/2013/340215
|
[40]
|
Chang, C.L.T, Liu, H.Y., Kuo, T.F., Hsu, Y.J., Shen, M.Y., Pan, C.Y., et al. (2013) Antidiabetic Effect and Mode of Action of Cytopiloyne. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID: 685642. https://doi.org/10.1155/2013/685642
|
[41]
|
Wei, W.S.V., Yang, W.C., Sheu, J.H., Shyur, L.F. and Yang, N.S. (2008) Cytopiloyne, A Polyacetylenic Glucoside from Bidens pilosa, Modulates T Cell Differentiation through Suppression of IL-12 Expression in Human Dendritic Cells. Planta Medica, 74, PA6. https://doi.org/10.1055/s-0028-1084006
|
[42]
|
Liang, Y.C., Yang, M.T., Lin, C.J., Chang, C.L.T. and Yang, W.C. (2016) Bidens pilosa and Its Active Compound Inhibit Adipogenesis and Lipid Accumulation via Down-Modulation of the C/EBP and PPARγ Pathways. Scientific Reports, 6, Article No. 24285. https://doi.org/10.1038/srep24285
|
[43]
|
Lai, B.Y., Chen, T.Y., Huang, S.H., Kuo, T.F., Chang, T.H., Chiang, C.K., et al. (2015) Bidens pilosa Formulation Improves Blood Homeostasis and β-Cell Function in Men: A Pilot Study. Evidence-Based Complementary and Alternative Medicine, 2015, Article ID: 832314. https://doi.org/10.1155/2015/832314
|
[44]
|
Hsu, Y.J., Lee, T.H., Chang, C.L.T., Huang, Y.T. and Yang, W.C. (2009) Anti-Hyperglycemic Effects and Mechanism of Bidens pilosa Water Extract. Journal of Ethnopharmacology, 122, 379-383. https://doi.org/10.1016/j.jep.2008.12.027
|
[45]
|
Kumar, C.R., Tsai, C.H., Chao, Y.S. and Lee, J.C. (2011) The First Total Synthesis of Cytopiloyne, An Anti-Diabetic, Polyacetylenic Glucoside. Chemistry, 17, 8696-8703. https://doi.org/10.1002/chem.201100986
|
[46]
|
Grossman, L.D., Roscoe, R. and Shack, A.R. (2018) Complementary and Alternative Medicine for Diabetes. Canadian Journal of Diabetes, 42, S154-S161. https://doi.org/10.1016/j.jcjd.2017.10.023
|
[47]
|
La Noce, M., Nicoletti, G.F., Papaccio, G., Del Vecchio, V. and Papaccio, F. (2022) Insulitis in Human Type 1 Diabetic Pancreas: From Stem Cell Grafting to Islet Organoids for a Successful Cell-Based Therapy. Cells, 11, Article No. 3941. https://doi.org/10.3390/cells11233941
|
[48]
|
Roep, B.O., Thomaidou, S., Van Tienhoven, R. and Zaldumbide, A. (2021) Type 1 Diabetes Mellitus as a Disease of the β-Cell (Do Not Blame the Immune System?). Nature Reviews Endocrinology, 17, 150-161. https://doi.org/10.1038/s41574-020-00443-4
|
[49]
|
Shen, M.Y., Lin, Y.P., Yang, B.C., Jang, Y.S., Chiang, C.K., Mettling, C., et al. (2012) Catenarin Prevents Type 1 Diabetes in Nonobese Diabetic Mice via Inhibition of Leukocyte Migration Involving the MEK6/P38 and MEK7/JNK Pathways. Evidence-Based Complementary and Alternative Medicine, 2012, Article ID: 982396. https://doi.org/10.1155/2012/982396
|
[50]
|
Campbell-Thompson, M., Fu, A., Kaddis, J.S., Wasserfall, C., Schatz, D.A., Pugliese, A., et al. (2016) Insulitis and β-Cell Mass in the Natural History of Type 1 Diabetes. Diabetes, 65, 719-731. https://doi.org/10.2337/db15-0779
|
[51]
|
Bulfoni, M., Bouyioukos, C., Zakaria, A., Nigon, F., Rapone, R., Del Maestro, L., Ait-Si-Ali, S., Scharfmann, R. and Cosson, B. (2022) Glucose Controls Co-Translation of Structurally Related mRNAs via the mTOR and eIF2 Pathways in Human Pancreatic Beta Cells. Frontiers in Endocrinology, 13, Article ID: 949097. https://doi.org/10.3389/fendo.2022.949097
|
[52]
|
Komatsu, M., Takei, M., Ishii, H. and Sato, Y. (2013) Glucose-Stimulated Insulin Secretion: A Newer Perspective. Journal of Diabetes Investigations, 4, 511-516. https://doi.org/10.1111/jdi.12094
|
[53]
|
Chen, Y.G., Mathews, C.E. and Driver, J.P. (2018) The Role of NOD Mice in Type 1 Diabetes Research: Lessons from the Past and Recommendations for the Future. Frontiers in Endocrinology, 9, Article No. 51. https://doi.org/10.3389/fendo.2018.00051
|
[54]
|
Oh, Y.S. (2015) Plant-Derived Compounds Targeting Pancreatic Beta Cells for the Treatment of Diabetes. Evidence-Based Complementary and Alternative Medicine, 2015, Article ID: 629863. https://doi.org/10.1155/2015/629863
|
[55]
|
Li, Y., Hong, W. and Li, L.-C. (2021) Pharmacogenomics of Insulin Secretagogues in Pharmacodynamics, Pharmacokinetics and Adverse Reactions. Austin Journal of Pharmacology and Therapeutics, 9, Article No. 1152.
|
[56]
|
Chang, C.L.T., Kuo, H.K., Chang, S.L., Chiang, Y.M., Lee, T.H., Wu, W.M., et al. (2005) The Distinct Effects of a Butanol Fraction of Bidens pilosa Plant Extract on the Development of Th1-Mediated Diabetes and Th2-Mediated Airway Inflammation in Mice. Journal of Biomedical Science, 12, 79-89. https://doi.org/10.1007/s11373-004-8172-x
|
[57]
|
Rodriguez-Mesa, X.M., Contreras, B.L.A., Mejía, A., Pombo, L.M., Modesti, C.G. and Santander, G.S.P. (2023) Immunomodulatory Properties of Natural Extracts and Compounds Derived from Bidens pilosa L.: Literature Review. Pharmaceutics, 15, Article No. 1491. https://doi.org/10.3390/pharmaceutics15051491
|
[58]
|
Apaya, M.K., Kuo, T.F., Yang, M.T., Yang, G., Hsiao, C.L., Chang, S.B., et al. (2020) Phytochemicals as Modulators of β-Cells and Immunity for the Therapy of Type 1 Diabetes: Recent Discoveries in Pharmacological Mechanisms and Clinical Potential. Pharmacology Research, 156, Article ID: 104754. https://doi.org/10.1016/j.phrs.2020.104754
|
[59]
|
Ajagun-Ogunleye, M.O., Tirwomwe, M., Mitaki, R.N., Ejekwumadu, J.N., Kasozi, K.I., Pantoglou, J., et al. (2015) Hypoglycemic and High Dosage Effects of Bidens pilosa in Type-1 Diabetes Mellitus. Journal of Diabetes Mellitus, 5, 146-154. https://doi.org/10.4236/jdm.2015.53018
|
[60]
|
Padhi, S., Nayak, A.K. and Behera, A. (2020) Type II Diabetes Mellitus: A Review on Recent Drug-Based Therapeutics. Biomedicine and Pharmacotherapy, 131, Article ID: 110708. https://doi.org/10.1016/j.biopha.2020.110708
|
[61]
|
Clark, M., Kroger, C.J. and Tisch, R.M. (2017) Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response. Frontiers in Immunology, 8, Article No. 1898. https://doi.org/10.3389/fimmu.2017.01898
|
[62]
|
Eisenbarth, G.S. (2004) Type 1 Diabetes: Molecular, Cellular and Clinical Immunology. Advances in Experimental Medicine and Biology, 552, 306-310.
|
[63]
|
Richardson, S.J., Willcox, A., Bone, A.J., Morgan, N.G. and Foulis, A.K. (2011) Immunopathology of the Human Pancreas in Type-I Diabetes. Seminars in Immunopathology, 33, 9-21. https://doi.org/10.1007/s00281-010-0205-0
|
[64]
|
Pugliese, A. (2017) Autoreactive T Cells in Type 1 Diabetes. Journal of Clinical Investigations, 127, 2881-2891. https://doi.org/10.1172/JCI94549
|
[65]
|
Gomez-Tourino, I., Arif, S., Eichmann, M. and Peakman, M. (2016) T Cells in Type 1 Diabetes: Instructors, Regulators and Effectors: A Comprehensive Review. Journal of Autoimmunity, 66, 7-16. https://doi.org/10.1016/j.jaut.2015.08.012
|
[66]
|
Clark, M., Kroger, C.J., Ke, Q. and Tisch, R.M. (2021) The Role of T Cell Receptor Signaling in the Development of Type 1 Diabetes. Frontiers in Immunology, 11, Article ID: 615371. https://doi.org/10.3389/fimmu.2020.615371
|
[67]
|
Burrack, A.L., Martinov, T. and Fife, B.T. (2017) T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes. Frontiers in Endocrinology, 8, Article No. 343. https://doi.org/10.3389/fendo.2017.00343
|
[68]
|
Willcox, A., Richardson, S.J., Bone, A.J., Foulis, A.K. and Morgan, N.G. (2009) Analysis of Islet Inflammation in Human Type 1 Diabetes. Clinical & Experimental Immunology, 155, 173-181. https://doi.org/10.1111/j.1365-2249.2008.03860.x
|
[69]
|
Arif, S., Gibson, V.B., Nguyen, V., Bingley, P.J., Todd, J.A., Guy, C., et al. (2017) β-Cell Specific T-Lymphocyte Response Has a Distinct Inflammatory Phenotype in Children with Type 1 Diabetes Compared with Adults. Diabetic Medicine, 34, 419-425. https://doi.org/10.1111/dme.13153
|
[70]
|
Ke, Q., Kroger, C.J., Clark, M. and Tisch, R.M. (2021) Evolving Antibody Therapies for the Treatment of Type 1 Diabetes. Frontiers in Immunology, 11, Article ID: 624568. https://doi.org/10.3389/fimmu.2020.624568
|
[71]
|
Anderson, M.S. and Bluestone, J.A. (2005) The NOD Mouse: A Model of Immune Dysregulation. Annual Review of Immunology, 23, 447-485. https://doi.org/10.1146/annurev.immunol.23.021704.115643
|
[72]
|
Pearson, J.A., Wong, F.S. and Wen, L. (2016) The Importance of the Non Obese Diabetic (NOD) Mouse Model in Autoimmune Diabetes. Journal of Autoimmunity, 66, 76-88. https://doi.org/10.1016/j.jaut.2015.08.019
|
[73]
|
Crawford, F., Stadinski, B., Jin, N., Michels, A., Nakayama, M., Pratt, P., et al. (2011) Specificity and Detection of Insulin-Reactive CD4+ T Cells in Type 1 Diabetes in the Nonobese Diabetic (NOD) Mouse. Proceedings of the National Academy of Sciences, 108, 16729-16734. https://doi.org/10.1073/pnas.1113954108
|
[74]
|
Babad, J., Geliebter, A. and DiLorenzo, T.P. (2010) T-Cell Autoantigens in the Non-Obese Diabetic Mouse Model of Autoimmune Diabetes. Immunology, 131, 459-465. https://doi.org/10.1111/j.1365-2567.2010.03362.x
|
[75]
|
Walker, L.S.K. and Von Herrath, M. (2016) CD4 T Cell Differentiation in Type 1 Diabetes. Clinical & Experimental Immunology, 183, 16-29. https://doi.org/10.1111/cei.12672
|
[76]
|
Lu, J., Liu, J., Li, L., Lan, Y. and Liang, Y. (2020) Cytokines in Type 1 Diabetes: Mechanisms of Action and Immunotherapeutic Targets. Clinical & Translational Immunology, 9, e1122. https://doi.org/10.1002/cti2.1122
|
[77]
|
DiMeglio, L.A., Evans-Molina, C. and Oram, R.A. (2018) Type 1 Diabetes. The Lancet, 391, 2449-2462. https://doi.org/10.1016/S0140-6736(18)31320-5
|
[78]
|
Wei, W.C., Liu, C.P., Yang, W.C., Shyur, L.F., Sheu, J.H., Chen, S.S., et al. (2015) Mammalian Target of Rapamycin Complex 2 (MTORC2) Regulates LPS-Induced Expression of IL-12 and IL-23 in Human Dendritic Cells. Journal of Leukocyte Biology, 97, 1071-1080. https://doi.org/10.1189/jlb.2A0414-206RR
|
[79]
|
Bairwa, K., Kumar, R., Sharma, R.J. and Roy, R.K. (2010) An Updated Review on Bidens pilosa L. Der Pharma Chemica, 2, 325-337.
|
[80]
|
Grant, B., Sandelson, M., Agyemang-Prempeh, B. and Zalin, A. (2021) Managing Obesity in People with Type 2 Diabetes. Clinical Medicine, 21, e327-e331. https://doi.org/10.7861/clinmed.2021-0370
|
[81]
|
Reed, J., Bain, S. and Kanamarlapudi, V. (2021) A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 14, 3567-3602. https://doi.org/10.2147/DMSO.S319895
|
[82]
|
Aronne, L.J., Hall, K.D., Jakicic, J., Leibel, R.L., Lowe, M.R., Rosenbaum, M., et al. (2021) Describing the Weight-Reduced State: Physiology, Behavior, and Interventions. Obesity (Silver Spring), 29, S9-S24. https://doi.org/10.1002/oby.23086
|
[83]
|
Hall, K.D. and Kahan S. (2018) Maintenance of Lost Weight and Long-Term Management of Obesity. Medical Clinics of North America, 102, 183-197. https://doi.org/10.1016/j.mcna.2017.08.012
|
[84]
|
Enright, C., Thomas, E. and Saxon, D.R. (2023) An Updated Approach to Antiobesity Pharmacotherapy: Moving beyond the 5% Weight Loss Goal. Journal of the Endocrine Society, 7, Bvac195. https://doi.org/10.1210/jendso/bvac195
|
[85]
|
Walmsley, R. and Sumithran, P. (2023) Current and Emerging Medications for the Management of Obesity in Adults. Medical Journal of Australia, 218, 276-283. https://doi.org/10.5694/mja2.51871
|
[86]
|
Czepiel, K.S., Perez, N.P., Campoverde, R.K.J., Sabharwal, S. and Stanford, F.C. (2020) Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US. Frontiers in Endocrinology, 11, Article No. 290. https://doi.org/10.3389/fendo.2020.00290
|
[87]
|
Müller, T.D., Blüher, M., Tschop, M.H. and DiMarchi, R.D. (2022) Anti-Obesity Drug Discovery: Advances and Challenges. Nature Reviews Drug Discovery, 21, 201-223. https://doi.org/10.1038/s41573-021-00337-8
|
[88]
|
Son, J. and Accili, D. (2023) Reversing Pancreatic β-Cell Dedifferentiation in the Treatment of Type 2 Diabetes. Experimental & Molecular Medicine, 55, 1652-1658. https://doi.org/10.1038/s12276-023-01043-8
|
[89]
|
Yun, J.W. (2010) Possible Anti-Obesity Therapeutics from Nature—A Review. Phytochemistry, 71, 1625-1641. https://doi.org/10.1016/j.phytochem.2010.07.011
|
[90]
|
Gamboa-Gómez, C.I., Rocha-Guzmán, N.E., Gallegos-Infante, J.A., Moreno-Jiménez, M.R., Vázquez-Cabral, B.D. and González-Laredo, R.F. (2015) Plants with Potential Use on Obesity and Its Complications. EXCLI Journal, 14, 809-831.
|
[91]
|
Farmer, S.R. (2008) Molecular Determinants of Brown Adipocyte Formation and Function. Genes & Development, 22, 1269-1275. https://doi.org/10.1101/gad.1681308
|
[92]
|
Moseti, D., Regassa, A. and Kim, W.K. (2016) Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive Molecules. International Journal of Molecular Sciences, 17, Article No. 124. https://doi.org/10.3390/ijms17010124
|
[93]
|
Siersbaek, R., Nielsen, R. and Mandrup, S. (2010) PPARgamma in Adipocyte Differentiation and Metabolism—Novel Insights from Genome-Wide Studies. FEBS Letters, 584, 3242-3249. https://doi.org/10.1016/j.febslet.2010.06.010
|
[94]
|
Barnes, P.M., Powell-Griner, E., McFann, K. and Nahin, R.L. (2004) Complementary and Alternative Medicine Use among Adults: United States, 2002. Seminars in Integrative Medicine, 2, 54-71. https://doi.org/10.1016/j.sigm.2004.07.003
|
[95]
|
Hasani-Ranjbar, S., Jouyandeh, Z. and Abdollahi, M. (2013) A Systematic Review of Anti-Obesity Medicinal Plants—An Update. Journal of Diabetes and Metabolic Disorders, 12, Article No. 28. https://doi.org/10.1186/2251-6581-12-28
|
[96]
|
Karri, S., Sharma, S., Hatware, K. and Patil, K. (2019) Natural Anti-Obesity Agents and Their Therapeutic Role in Management of Obesity: A Future Trend Perspective. Biomedicine and Pharmacotherapy, 110, 224-238. https://doi.org/10.1016/j.biopha.2018.11.076
|
[97]
|
Mir, S.A., Shah, M.A., Ganai, S.A., Ahmad, T. and Gani, M. (2019) Understanding the Role of Active Components from Plant Sources in Obesity Management. Journal of the Saudi Society of Agricultural Sciences, 18, 168-176. https://doi.org/10.1016/j.jssas.2017.04.003
|